Αρχική World News EMA Recommends Refusal of the Marketing Authorisation for Pexidartinib

EMA Recommends Refusal of the Marketing Authorisation for Pexidartinib

The European Medicines Agency (EMA) has recommended the refusal of the marketing authorisation for pexidartinib (Turalio), a medicine intended for the treatment of tenosynovial giant cell tumour.

The Agency issued its opinion on 25 June 2020. The company that applied for authorisation, Daiichi Sankyo Europe GmbH, may ask for re-examination of the opinion within 15 days of receiving the opinion.

Turalio was developed as a medicine for treating adults with tenosynovial giant cell tumour that can cause pain and markedly reduce physical function. It was for use when other treatments, including surgery, could no longer be used or were unsuitable. Tenosynovial giant cell tumour is a noncancerous condition in which the tissue surrounding the inner joint surfaces and tendons, called the synovial lining or synovium, expands abnormally and forms growths in and around the joint.

Turalio contains the active substance pexidartinib and was to be available as capsules.

Turalio was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 March 2015 for the treatment of tenosynovial giant cell tumour, localised and diffuse type.

The active substance in Turalio, pexidartinib, works by blocking a receptor called CSF1R to which a protein called CSF-1 attaches. CSF-1 is produced in large amounts by tenosynovial giant cell tumours, and it causes immune cells called macrophages to build up in the joints and cause the outgrowths. By blocking CSF1R, the medicine reduces the activity of CSF-1, which was expected to prevent tumour growth and help to reduce symptoms of the disease.

To support its application, the company presented results from a main study involving 120 adults with advanced tenosynovial giant cell tumour that could not be treated in other ways. It looked at the change in tumour size after patients received either Turalio or placebo for 25 weeks.

The Agency was concerned that although the main study found that tumours shrank in patients treated with Turalio, there was only a small improvement in symptoms such as pain and the ability to use the joint. It was not clear how long this effect lasts. There was also serious concern about unpredictable, potentially life-threatening effects of Turalio on the liver. Therefore, the Agency’s opinion was that the benefits of Turalio did not outweigh its risks and it recommended refusing marketing authorisation.

The company informed the Agency that there are no consequences for patients in clinical trials or in compassionate use programmes with Turalio.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...
- Advertisment -

Ροή Ειδήσεων

Woman Dances Through Chemo Sessions, Emphasizes Importances of Being ‘Joyful’

Rena Williams radiates positivity and joy. According to friends, family, and coworkers, this has always been true of Rena, and she wasn’t about to...

Coronavirus reports – Part 9: “I am very relieved but I am not naïve”

Max and his wife We caught up with people living with cancer across the country, to find out how the coronavirus pandemic has been affecting...

Answers to Your Questions About the COVID-19 Vaccine

Julie Gralow, MD, FACP, FASCO, is the Chief Medical Officer (CMO) and Executive Vice President of the American Society of Clinical Oncology (ASCO). Previously, she...

The OncoLife Survivorship Care Plan: An Educational Tool For Survivors That Has Educated Us

In April of 2007, OncoLink launched the OncoLife Survivorship Care Plan, a tool to create care plans for people who have survived cancer. As...

EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab

On 25 February 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change...

Daughter Donates Hair to Mother After She Was Diagnosed with Stage IV Breast Cancer

Marybeth Kersey has wanted to donate her hair to her mother, Lynn Hier, since she first found out she had stage I breast cancer....